Diverse Imaging Methods May Influence Long-Term Oncologic Outcomes in Oligorecurrent Prostate Cancer Patients Treated with Metastasis-Directed Therapy (the PRECISE-MDT Study).
PET
choline
metastasis-directed therapy
oligorecurrent prostate cancer
prostate-specific membrane antigen
Journal
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN: 1535-5667
Titre abrégé: J Nucl Med
Pays: United States
ID NLM: 0217410
Informations de publication
Date de publication:
21 Jun 2024
21 Jun 2024
Historique:
received:
09
02
2024
accepted:
09
05
2024
medline:
22
6
2024
pubmed:
22
6
2024
entrez:
21
6
2024
Statut:
aheadofprint
Résumé
Metastasis-directed therapy (MDT) has been tested in clinical trials as a treatment option for oligorecurrent prostate cancer (PCa). However, there is an ongoing debate regarding the impact of using different imaging techniques interchangeably for defining lesions and guiding MDT within clinical trials.
Identifiants
pubmed: 38906557
pii: jnumed.124.267586
doi: 10.2967/jnumed.124.267586
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 by the Society of Nuclear Medicine and Molecular Imaging.